Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients
Identifieur interne : 001696 ( Main/Exploration ); précédent : 001695; suivant : 001697Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients
Auteurs : Tuvia Hadar ; Jack Sidi ; Menashe Rahima ; Erika Rakowsky ; Ernesto Kahan ; Batya Sarov [Israël] ; Batya Sarov [Israël]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 1986-12.
English descriptors
Abstract
The feasibility of using elevated Epstein‐Barr virus (EBV) specific‐IgG antiviral capsid antigen (VCA) and IgA anti‐VCA antibody levels as an aid in diagnosis of nasopharyngeal carcinoma (NPC) was analyzed by determination of serum anti‐body titers to EBV in 54 NPC patients, 114 healthy blood donors, and 40 family members by the immunoperoxidase assay (IPA). No significant difference was found in the prevalence rate of EBV IgG anti‐VCA antibodies (titer ≥20) between the patient group and the control and family groups (100% vs 92% and 90%, respectively). The prevalence rate of elevated EBV IgG anti‐VCA titers (≥ 80, ≥ 160, ≥ 320, and≥ 640) was significantly higher in the NPC patients than in controls. For example, at an IgG titer of ≥320, the prevalence rate was 82% in the NPC patient group and 1.7% in the controls (P <0.0001). The prevalence of EBV IgA anti‐VCA antibodies (≥ 10) was significantly higher in the NPC patients than in control and family groups (82% vs 6.1% and 0%, respectively). The prevalence rate for elevated EBV IgA anti‐VCA (≥20) was found to be significantly higher (P <0.0001) in NPC patients than in the control group (70% vs 1.7%). A significantly high proportion (P = 0.0004) of NPC patients who had serum EBV IgA anti‐VCA titers of <20 had elevated IgG titers to VCA ≥ 320 (21 % vs 1.7% among controls). It appears that testing for IgG antibodies at a serum dilution of 1:320 and for IgA antibodies at a dilution of 1:20 by the IPA technique comprises the best combination for the differentiation between NPC patients and health controls (91% vs 3.4%), and it is suggested that these be used as screening markers for NPC patients.
Url:
DOI: 10.1002/jmv.1890200405
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001111
- to stream Istex, to step Curation: 000C37
- to stream Istex, to step Checkpoint: 000E68
- to stream Main, to step Merge: 001756
- to stream Main, to step Curation: 001696
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients</title><author><name sortKey="Hadar, Tuvia" sort="Hadar, Tuvia" uniqKey="Hadar T" first="Tuvia" last="Hadar">Tuvia Hadar</name></author><author><name sortKey="Sidi, Jack" sort="Sidi, Jack" uniqKey="Sidi J" first="Jack" last="Sidi">Jack Sidi</name></author><author><name sortKey="Rahima, Menashe" sort="Rahima, Menashe" uniqKey="Rahima M" first="Menashe" last="Rahima">Menashe Rahima</name></author><author><name sortKey="Rakowsky, Erika" sort="Rakowsky, Erika" uniqKey="Rakowsky E" first="Erika" last="Rakowsky">Erika Rakowsky</name></author><author><name sortKey="Kahan, Ernesto" sort="Kahan, Ernesto" uniqKey="Kahan E" first="Ernesto" last="Kahan">Ernesto Kahan</name></author><author><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name></author><author><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9E14BD34D564FEE6884E201A4CA148D18DCCC298</idno><date when="1986" year="1986">1986</date><idno type="doi">10.1002/jmv.1890200405</idno><idno type="url">https://api.istex.fr/document/9E14BD34D564FEE6884E201A4CA148D18DCCC298/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001111</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001111</idno><idno type="wicri:Area/Istex/Curation">000C37</idno><idno type="wicri:Area/Istex/Checkpoint">000E68</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E68</idno><idno type="wicri:doubleKey">0146-6615:1986:Hadar T:significance:of:specific</idno><idno type="wicri:Area/Main/Merge">001756</idno><idno type="wicri:Area/Main/Curation">001696</idno><idno type="wicri:Area/Main/Exploration">001696</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients</title><author><name sortKey="Hadar, Tuvia" sort="Hadar, Tuvia" uniqKey="Hadar T" first="Tuvia" last="Hadar">Tuvia Hadar</name><affiliation><wicri:noCountry code="subField">Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Sidi, Jack" sort="Sidi, Jack" uniqKey="Sidi J" first="Jack" last="Sidi">Jack Sidi</name><affiliation><wicri:noCountry code="subField">Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Rahima, Menashe" sort="Rahima, Menashe" uniqKey="Rahima M" first="Menashe" last="Rahima">Menashe Rahima</name><affiliation><wicri:noCountry code="subField">Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Rakowsky, Erika" sort="Rakowsky, Erika" uniqKey="Rakowsky E" first="Erika" last="Rakowsky">Erika Rakowsky</name><affiliation><wicri:noCountry code="subField">Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Kahan, Ernesto" sort="Kahan, Ernesto" uniqKey="Kahan E" first="Ernesto" last="Kahan">Ernesto Kahan</name><affiliation><wicri:noCountry code="subField">Aviv</wicri:noCountry></affiliation></author><author><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Epidemiology, Soroka University Hospital and Faculty of Sciences, Ben Gurion University of the Negev, Beer Sheva</wicri:regionArea><wicri:noRegion>Beer Sheva</wicri:noRegion></affiliation></author><author><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Virology Units, Soroka University Hospital and Faculty of Sciences, Ben Gurion University of the Negev, Beer Sheva</wicri:regionArea><wicri:noRegion>Beer Sheva</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Medical Virology</title><title level="j" type="abbrev">J. Med. Virol.</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1986-12">1986-12</date><biblScope unit="volume">20</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="329">329</biblScope><biblScope unit="page" to="339">339</biblScope></imprint><idno type="ISSN">0146-6615</idno></series><idno type="istex">9E14BD34D564FEE6884E201A4CA148D18DCCC298</idno><idno type="DOI">10.1002/jmv.1890200405</idno><idno type="ArticleID">JMV1890200405</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>EBVIgG and IgA antibodies</term><term>nasopharyngeal carcinoma</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The feasibility of using elevated Epstein‐Barr virus (EBV) specific‐IgG antiviral capsid antigen (VCA) and IgA anti‐VCA antibody levels as an aid in diagnosis of nasopharyngeal carcinoma (NPC) was analyzed by determination of serum anti‐body titers to EBV in 54 NPC patients, 114 healthy blood donors, and 40 family members by the immunoperoxidase assay (IPA). No significant difference was found in the prevalence rate of EBV IgG anti‐VCA antibodies (titer ≥20) between the patient group and the control and family groups (100% vs 92% and 90%, respectively). The prevalence rate of elevated EBV IgG anti‐VCA titers (≥ 80, ≥ 160, ≥ 320, and≥ 640) was significantly higher in the NPC patients than in controls. For example, at an IgG titer of ≥320, the prevalence rate was 82% in the NPC patient group and 1.7% in the controls (P <0.0001). The prevalence of EBV IgA anti‐VCA antibodies (≥ 10) was significantly higher in the NPC patients than in control and family groups (82% vs 6.1% and 0%, respectively). The prevalence rate for elevated EBV IgA anti‐VCA (≥20) was found to be significantly higher (P <0.0001) in NPC patients than in the control group (70% vs 1.7%). A significantly high proportion (P = 0.0004) of NPC patients who had serum EBV IgA anti‐VCA titers of <20 had elevated IgG titers to VCA ≥ 320 (21 % vs 1.7% among controls). It appears that testing for IgG antibodies at a serum dilution of 1:320 and for IgA antibodies at a dilution of 1:20 by the IPA technique comprises the best combination for the differentiation between NPC patients and health controls (91% vs 3.4%), and it is suggested that these be used as screening markers for NPC patients.</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><noCountry><name sortKey="Hadar, Tuvia" sort="Hadar, Tuvia" uniqKey="Hadar T" first="Tuvia" last="Hadar">Tuvia Hadar</name><name sortKey="Kahan, Ernesto" sort="Kahan, Ernesto" uniqKey="Kahan E" first="Ernesto" last="Kahan">Ernesto Kahan</name><name sortKey="Rahima, Menashe" sort="Rahima, Menashe" uniqKey="Rahima M" first="Menashe" last="Rahima">Menashe Rahima</name><name sortKey="Rakowsky, Erika" sort="Rakowsky, Erika" uniqKey="Rakowsky E" first="Erika" last="Rakowsky">Erika Rakowsky</name><name sortKey="Sidi, Jack" sort="Sidi, Jack" uniqKey="Sidi J" first="Jack" last="Sidi">Jack Sidi</name></noCountry><country name="Israël"><noRegion><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name></noRegion><name sortKey="Sarov, Batya" sort="Sarov, Batya" uniqKey="Sarov B" first="Batya" last="Sarov">Batya Sarov</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001696 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001696 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= CobaltMaghrebV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:9E14BD34D564FEE6884E201A4CA148D18DCCC298
|texte= Significance of Specific Epstein‐Barr Virus IgA and Elevated IgG Antibodies to Viral Capsid Antigens in Nasopharyngeal Carcinoma Patients
}}
| This area was generated with Dilib version V0.6.32. |  |